linkedin
BROUGHT TO YOU BY
Exclusive Access, Inclusive Growth

WELCOME TO ET PRIME

BROUGTH TO YOU BY
Exclusive Access, Inclusive Growth

Pharma

1
Pharma

Favipiravir has limited efficacy data, but doctors still go for Glenmark's drug to cope with a crisis

Last month, India’s drug regulator granted emergency-use authorisation for favipiravir to treat Covid-19, making it the first oral anti-viral drug approved for such use. However, Glenmark, which launched the favipiravir brand FabiFlu, hasn’t yet disclosed data of its clinical trial on 150 patients to assess the drug’s safety and efficacy. This is causing concern among doctors and public-health experts.

Pharma

Japan’s AnGes preps capacity for 1 million doses as vaccine development continues

The country hopes to counter any second wave of infections by building production capacity while vaccines are still in the works. AnGes is developing a DNA vaccine that will use genetic material from the coronavirus to stimulate the production of human antibodies against the disease. The vaccine is expected to begin clinical trials soon.

12 Jul 20200 comment
[[^message]]

Result

[[/message]] [[#message]]

[[message]]

[[/message]]